摘要
Abstract
AIM: To investigate the clinical efficacy of intravitreal injection of Ranibizumab combined with pars plana vitrectomy ( PPV ) in patients with proliferative diabetic retinopathy ( PDR ) complicated with early neovascular glaucoma.? METHODS: Totally 80 patients ( 80 eyes ) of PDR patients with early neovascular glaucoma were selected in the patients went to Ophthalmic Center from July 2014 to December 2016. According to whether the injection of ranibizumab taken, they were divided as pretreatment group ( 40 patients 40 eyes, preoperative ranibizumab injection combined with PPV treatment ) , conventional group (40 patients 40 eyes, only taken PPV surgery). The changes of visual acuity, intraocular pressure and other indicators were compared between the two groups.?RESULTS: The operation time, neovascular bleeding times, coagulation times of pretreatment groups were significantly lower than those of the conventional group, the differences were statistically significant (P<0. 05). The differences of preoperative intraocular pressure, BCVA between the two groups were not statistically significant (P>0. 05). At 1wk, 3mo after the surgery, the BCVA of pretreatment group was better than that of conventional group (P<0. 05). At 1wk after the operation, the IOP of pretreatment group were lower than that of conventional group ( P< 0. 05 ). The preoperative VEGF in aqueous humor of the two groups was not significantly different (P>0. 05 ). At 1mo after operation, VEGF in aqueous humor of the pretreatment group was significantly lower than conventional group ( P < 0. 05 ). At 3mo after operation, the fovea retinal thickness of pretreatment group was lower than that of the conventional group ( P<0. 05).?CONCLUSION: Ranibizumab combined with PPV can significantly reduce the difficulty of operation in PDR patients with early neovascular glaucoma, improve the postoperative visual acuity, and reduce the level of VEGF in aqueous humor.关键词
增生/糖尿病视网膜病变/青光眼/雷珠单抗/玻璃体切割术Key words
proliferative/diabetic retinopathy/glaucoma/ranibizumab/vitrectomy
